Degludec is an ultralong-acting insulin analogue with a flat and reproducible pharmacodynamic profile. As some patients with type 1 diabetes (T1D) fail to achieve 24-h coverage with glargine or detemir despite twice-daily injections, we studied the effect of switching T1D patients from twice-daily glargine or detemir to degludec.
Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study
GALASSO, SILVIA;FACCHINETTI, ANDREA;Bonora, B. M;MARIANO, VALENTINA;BOSCARI, FEDERICO;CIPPONERI, ELISA;MARAN, ALBERTO;AVOGARO, ANGELO;FADINI, GIAN PAOLO;BRUTTOMESSO, DANIELA
2016
Abstract
Degludec is an ultralong-acting insulin analogue with a flat and reproducible pharmacodynamic profile. As some patients with type 1 diabetes (T1D) fail to achieve 24-h coverage with glargine or detemir despite twice-daily injections, we studied the effect of switching T1D patients from twice-daily glargine or detemir to degludec.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
